manag view appreci
sale guid in-lin expect ep
manag guidanc commentari come welcom
surpris uncertain time mani investor expect ew suspend guidanc given
uncertainti relat pandem pleasantli surpris
guidanc color manag provid sale ep
compani major busi line although procedur volum current
signific pressur us europ japan manag encourag earli
sign region take step toward increas elect procedur
come week month given ew leadership larg expand
tavr market continu recommend ew name reiter
outperform rate ew rais target price
guidanc bracket prior estim tavr total sale
ep guid come estim management new sale ep guidanc
bil reflect sharp impact
pandem follow gradual recoveri growth in-
line prior expect management trim tavr growth expect roughli flat
vs previou guidanc
stronger expect sale ep cse con tavr
us drove upsid rel estim mm savr mm
critic mm roughli in-lin ep ahead
estim street
chang model weve trim sale estim mil
bil y/i org rais ep estim
valuat target price base ebitda multipl
unchang estim ntm ebitda one-year forward bil unchang
increas target driven primarili lower share risk product delay greater
share loss litig regulatory/qu issu risk relat
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
global manufactur provid
medic devic equip structur valvular heart diseas
critic care
one-year valuat scenario base
ev/ebitda multipl estim ntm ebitda one-year forward
one-year valuat grey scenario base
ev/ebitda multipl estim ntm ebitda one-year forward
 close
addit detail takeaway
tavr sale grew organ despit challeng associ ww tavr
sale consist earli march slowdown procedur volum
last week quarter result tavr sale
y/i driven increas tavr treatment manag expect pressur
tavr volum pronounc ou tavr sale grew cc driven
strong growth europ tavr sale japan driven
strong adopt meaning impact howev management expect
neg impact sapien ultra uptak continu strong account
 european tavr volum howev compani made decis
paus enrol new center due said management indic structur
heart patient delay treatment eventu get treat cite data publish
annal thorac surgeri suggest patient wait aortic valv
replac mortal risk month month wait
month compani expect underli sale growth rang vs
previou expect tavr sale growth rate around top rang
tmtt slow mitral tricuspid progress
tmtt sale mil driven strong momentum on-going adopt pascal
europ ew also temporarili paus new clinic trial enrol mitral
tricuspid management continu expect bil market opportun
compani expect tmtt sale mil previou rang mil
sale declin result lower surgic aortic valv procedur tavr
adopt increas addit last week march ew experienc sharp
deceler procedur relat impact compani also cite on-going
adopt inspiri resilia aortic valv addit compani commerci launch
harpoon europ receiv regulatori approv ew expect begin enrol
 pivot studi compani lower guidanc
sale y/i driven increas demand europ ew truwav dispos
pressur monitor devic partial off-set lower demand enhanc surgic recoveri
product critic focus help patient requir hemodynam monitor
surgic set larger percentag also patient requir support icu smaller
percentag result revenu ew enhanc surgic recoveri
product expect significantli lower partial off-set increas demand icu
product management also cite delay hemospher order hospit limit
capit spend compani expect sale rang
compani lower sale rang bil bil result
impact management expect impact
sale sever follow gradual recoveri
close resembl compani origin expect sale compani expect
tavr growth rang vs previou expect tavr sale
growth rate around top rang ep guidanc also reduc
fx expect neg impact sale
mil previous compani expect sale mill
bottom line sale net cog lower sg lower share
partial off-set higher non-op higher tax rate deliv ep
estim gross margin bp y/i fx impact
gm bp
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto april
chang model
decreas sale estim increas ep estim
in-lin new guidanc also made minor adjust top-lin project
beyond increas sale estim outer year ep estim rise
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
